William Blair & Company
GHDX

William Blair & Company’s Genomic Health, Inc. GHDX Stock Holding History

William Blair & Company’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,800
Closed -$407K – 1822
2018
Q3 		$407K Buy
5,800
+1,600
+38% +$93.6K ﹤0.01% 1031
2018
Q2 		$212K Buy
+4,200
New +$167K ﹤0.01% 1249
2015
Q1 		– Sell
-27,260
Closed -$871K – 2223
2014
Q4 		$871K Sell
27,260
-650
-2% -$21.2K ﹤0.01% 1536
2014
Q3 		$790K Sell
27,910
-700
-2% -$19.5K ﹤0.01% 1550
2014
Q2 		$783K Sell
28,610
-350
-1% -$9.32K ﹤0.01% 1531
2014
Q1 		$762K Buy
28,960
+7,260
+33% +$208K ﹤0.01% 1493
2013
Q4 		$635K Buy
21,700
+1,200
+6% +$38.1K ﹤0.01% 1518
2013
Q3 		$626K Sell
20,500
-550
-3% -$18.4K ﹤0.01% 1486
2013
Q2 		$667K Buy
+21,050
New +$691K ﹤0.01% 1409

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair & Company's GHDX Position: Q4 2018 in Review

William Blair & Company sold out of Genomic Health, Inc. (GHDX) in Q4 2018, closing a stake of 5,800 shares — an estimated $407K sold.

William Blair & Company first reported a position in GHDX in Q2 2013 and held it in 9 quarters. The position peaked at $871K in Q4 2014. 228 funds tracked by Wall St. Rank hold GHDX as of Q4 2018.

  • William Blair & Company reported no remaining Genomic Health, Inc. position as of Q4 2018 after selling out during the quarter.
  • William Blair & Company sold 5,800 Genomic Health, Inc. shares in Q4 2018, an estimated $407K.
  • William Blair & Company first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 9 quarters.
  • William Blair & Company's Genomic Health, Inc. position peaked at $871K in Q4 2014.
  • 228 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2018.

Based on William Blair & Company's 13F filing for Q4 2018, filed 14 Feb 2019.